Department of Psychiatry, University of Newcastle upon Tyne, UK.
Addict Biol. 1999 Apr;4(2):111-26. doi: 10.1080/13556219971623.
Cannabinoids appear to be of therapeutic value as antiemetics, antispasmodics, analgesics and appetite stimulants and may have potential uses in epilepsy, glaucoma and asthma. Scientific evidence for any of these indications, except for antiemetic effects, is extremely sparse and claims for clinical utility are largely based on anecdotal reports. Furthermore, the mechanisms of action of any of the therapeutic effects are unknown. This paper reviews the clinical trials which have been carried out with cannabinoids including Δ⁹-tetrahydrocannabinol (THC) and synthetic cannabinoids such as nabilone and levonantradol, and discusses the advantages and adverse effects of cannabinoids in clinical use. The place of cannabinoids in modern medicine remains to be properly evaluated, but present evidence suggests that they could be valuable, particularly as adjuvants, for symptom control in a range of conditions for which standard drugs are not fully satisfactory.
大麻素类药物似乎具有作为止吐剂、抗痉挛药、镇痛药和食欲刺激剂的治疗价值，并且可能在癫痫、青光眼和哮喘中具有潜在用途。除了止吐作用外，这些适应症中的任何一种的科学证据都极其稀少，并且对临床应用的主张主要基于传闻报告。此外，任何治疗效果的作用机制都不清楚。本文综述了已进行的大麻素类药物临床试验，包括 Δ⁹-四氢大麻酚（THC）和合成大麻素如纳布啡和左洛那他定，并讨论了大麻素类药物在临床应用中的优点和不良反应。大麻素类药物在现代医学中的地位仍有待适当评估，但现有证据表明，它们可能具有价值，特别是作为辅助药物，用于控制一系列标准药物不完全令人满意的疾病的症状。
